AGTC receives grant to evaluate Phase II Human Clinical Trial for LCA retinal disease

Applied Genetic Technologies Corporation, a privately-held, clinical stage biotechnology company developing novel systems to deliver human therapeutics, announces that it has received a grant of $1 million from the Food and Drug Administration (FDA Orphan Drugs Program). The grant will fund a Phase II Human Clinical Trial evaluating the safety and efficacy of a treatment for Leber congenital amaurosis (LCA), a genetic retinal disease known to cause blindness at an early age. The clinical trial, coordinated by AGTC, is being conducted at The University of Massachusetts Medical School by Dr. Shalesh Kaushal and Oregon Health & Science University by Dr. Tim Stout.

“We are pleased that the FDA and its grant reviewers recognized AGTC's expertise in clinical development of treatments for genetic retinal disease”

"We are pleased that the FDA and its grant reviewers recognized AGTC's expertise in clinical development of treatments for genetic retinal disease," said Sue Washer, President and CEO of AGTC. "This funding will enable us to complete enrollment of the Phase 2 trial that is designed to deliver recombinant adeno-associated virus (rAAV) vectors to larger areas of the retina than in clinical studies performed to date. The ultimate goal of this research is to improve the sight and quality of life of patients affected by this disorder. We continue to be encouraged by the data from this and other trials supporting the ability of rAAV to provide sustained delivery and expression of therapeutic levels of many different biologics in the eye."

"I am excited about the opportunity to offer my patients with LCA the opportunity to participate in this clinical trial," said Tim Stout, M.D., vice president and professor of ophthalmology, Casey Eye Institute, OHSU School of Medicine. "The orphan program is an important mechanism that enables clinical development of these kinds of treatments."

Source:

: Applied Genetic Technologies Corporation

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Weight loss drug semaglutide may offer relief for knee arthritis pain